1.	Phase III Randomized Study of ICI 182780 (Faslodex) versus Anastrozole in Postmenopausal Women with Advanced Breast Cancer (Summary Last Modified 11/1999) Phase: Phase III Type: Treatment Status: Closed Age: Not specified Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: RPCI-DS-97-29, ZENECA-9238IL/0021, NCI-G98-1412
2.	S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: Postmenopausal Sponsor: NCI, Other Protocol IDs: CDR0000349337, U10CA032102, S0226, CAN-NCIC-MAC7, SWOG-S0226, NCT00075764
3.	The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: Postmenopausal Sponsor: Pharmaceutical / Industry Protocol IDs: 9238IL/0048, EFECT, D6997C00048, NCT00065325
4.	Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D6997C00002, NCT00099437
5.	Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: Any age Sponsor: Other Protocol IDs: CDR0000448616, ICR-CTSU-SOFEA, EU-20531, SSA-04Q200635, ISRCTN44195747, MREC-03677, EUDRACT-2004-000093-30, NCT00253422
6.	Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy Phase: Phase III Type: Treatment Status: Completed Age: No age specified Sponsor: Pharmaceutical / Industry Protocol IDs: D6997L00002, 9238SW/0001, FACT, NCT00256698
7.	Faslodex Advanced Breast Cancer Local Chinese Study Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D6997L00004, NCT00327769
8.	Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00475, 40302, U10CA031946, CDR0000510452, CALGB-40302, NCT00390455
9.	Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI) Phase: Phase III Type: Treatment Status: Completed Age: Postmenopausal Sponsor: Pharmaceutical / Industry Protocol IDs: 9238UK/0005, NCT00944918
10.	Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 2008-0336, NCT00903006
11.	Phase II Study of Fulvestrant in Patients With Newly Recurrent, Persistent, or Metastatic Endometrial Cancer Phase: Phase II Type: Treatment Status: Closed Age: Not specified Sponsor: NCI Protocol IDs: GOG-0188, NCT00006903
12.	Phase II Study of Fulvestrant (ICI 182780) in Women With Metastatic Breast Cancer Who Have Failed Aromatase Inhibitor Therapy Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N0032, N0032, NCT00012025
13.	Anastrozole & ZD1839 Compared With Fulvestrant & ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000285631, U10CA021115, E4101, ECOG-4101, NCT00057941
14.	Tipifarnib and Fulvestrant as Second-Line Therapy in Treating Postmenopausal Women With Hormone Receptor-Positive Inoperable Locally Advanced or Metastatic Breast Cancer With Progressive Disease After Previous First-Line Endocrine Therapy Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000360837, AECM-0104-085, NCI-6205, 6205, NCT00082810
15.	Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: Postmenopausal Sponsor: Pharmaceutical / Industry Protocol IDs: 9238IL/0065, D6997C00003, NCT00093002
16.	Fulvestrant in Treating Patients With Advanced Prostate Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CDR0000447133, RPCI-I-53805, NCT00244998
17.	Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 04-075, NCT00146601
18.	Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: OSU-0494, NCI-2011-03154, NCT00201864
19.	Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: H-14732, NCT00206414
20.	A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1839IL/0141, NCT00234403
21.	Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D6997C00057, 9238IL/0057, NCT00259090
22.	A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: D6995C00006, FIRST, NCT00274469
23.	A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg Phase: Phase II Type: Treatment Status: Completed Age: Postmenopausal Sponsor: Pharmaceutical / Industry Protocol IDs: D6997C00004, FINDER I, NCT00305448
24.	A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg Phase: Phase II Type: Treatment Status: Closed Age: No age specified Sponsor: Pharmaceutical / Industry Protocol IDs: D6997C00006, FINDER II, NCT00313170
25.	Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma. Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9238GR/0002, NCT00334295